ArticleForum for health economics & policy2024
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices.
Article in Forum for health economics & policy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Including Productivity as an Element to Reflect Value of the Treatment: A Systematic Review of Published Health Economic Evaluations.PharmacoEconomics - open · 2025Pooled it
- Bridging the divide between health economics and outcomes research and biomedical investment: reflections from a health economist working in venture capital.Journal of comparative effectiveness research · 2026Review
- Spillover Effects of Medical Innovations: A Universal and Scalable Approach to Measure the Societal Value of Avoided Informal Care Time.Applied health economics and health policy · 2026Article
- Action Plan to Better Approximate Reality in Cost-Effectiveness Analyses.Applied health economics and health policy · 2026Article
- Economic value of ribociclib in early breast cancer in the United States.Journal of managed care & specialty pharmacy · 2026Article
- Advancing the measurement of caregiver impact: Data collection priorities aligned with caregiver, health technology assessment, and policy stakeholders.Journal of managed care & specialty pharmacy · 2026Review
- Estimating the societal impact of medical interventions: a case study in metastatic breast cancer.Journal of comparative effectiveness research · 2026Article
- The inaugural HEMA report: a missed opportunity for comprehensive value assessment.Journal of comparative effectiveness research · 2026Article
- The broad societal value of pembrolizumab for women's cancer in Canada.Future oncology (London, England) · 2026Article
- Taxonomy of the Full Health and Societal Value of Maternal Vaccination to Prevent Infant Respiratory Syncytial Virus Disease.Infectious diseases and therapy · 2026Review
- Measuring and valuing spillover effects in caregivers and families: A scoping review.PloS one · 2026Article
- A novel framework to assess the prevention value of a health intervention.Diabetes, obesity & metabolism · 2026Review
- Leprosy elimination: are we winning the fight or losing focus?Annals of medicine · 2025Article
- Access in all areas? A round up of developments in market access and health technology assessment: part 9.Journal of comparative effectiveness research · 2025Article
- Cost-effectiveness analysis model for sotagliflozin compared with insulin monotherapy for patients with type 1 diabetes and chronic kidney disease.Journal of managed care & specialty pharmacy · 2025Article
- Improving access to innovation from international health technology assessment.International journal of technology assessment in health care · 2025Article
- A Review of Heterogeneity in Comparative Economic Analysis, with Specific Considerations for the Decentralized US Setting and Patient-Centered Care.PharmacoEconomics · 2025Review
- Health technology assessment of surgical robots: a mini-review of a rapidly evolving field.Frontiers in public health · 2025Review
- Generalized cost-effectiveness analysis: charting a path forward for measuring the societal value of medical technologies.Journal of comparative effectiveness research · 2025Article
- Consequences of Canada's Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access.ClinicoEconomics and outcomes research : CEOR · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
This study argues that value assessment conducted from a societal perspective should rely on the Generalized Cost-Effectiveness Analysis (GCEA) framework proposed herein. Recently developed value assessment inventories - such as the Second Panel on Cost-Effectiveness's "impact inventory" and International Society of Pharmacoeconomics Outcomes Research (ISPOR) "value flower" - aimed to more comprehensively capture the benefits and costs of new health technologies from a societal perspective. Nevertheless, application of broader value elements in practice has been limited in part because quantifying these elements can be complex, but also because there have been numerous methodological advances since these value inventories have been released (e.g. generalized and risk-adjusted cost effectiveness). To facilitate estimation of treatment value from a societal perspective, this paper provides an updated value inventory - called the GCEA value flower - and a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.